US 11447830
Gene signatures to predict drug response in cancer
granted A61PA61P35/00
Quick answer
US patent 11447830 (Gene signatures to predict drug response in cancer) held by The Board of Regents of the University of Texas System expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61P, A61P35/00